With rich experience in antibody discovery and membrane protein studies, experts from Creative Biolabs have launched a cutting-edge membrane protein antibody development platform. Particularly, we now provide all-around service of anti-GPCR membrane protein antibody discovery service against a variety of GPCR targets.
Being the largest membrane receptor family, G-protein-coupled receptors (GPCRs) have more than 800 members, about 370 of which are regarded as important therapeutic targets in clinic. Currently, there are about 30% of marketed drugs that exert the intended effects through modulation of GPCRs. Especially, antibodies against GPCRs are drawing increasing research interest due to their high specificity, high affinity, good developability and low cytotoxicity in contrast to small molecules. However, due to the complicated structure and low expression level of most GPCRs, anti-GPCR antibody development is very challenging. To overcome these issues and save valuable time for our clients, Creative Biolabs has integrated multiple state-of-the-art technologies for robust antibody generation against GPCRs:
Fig 1. Typical structure of G-protein-coupled receptors (GPCR).
Creative Biolabs has extensive experience in hybridoma technology. Our hybridoma platform offers both mouse and rat animal models to raise anti-GPCR antibodies. Vigorous immune response and high cell fusion efficacy can be guaranteed, followed by comprehensive screening of large candidate pools. Our team is specialized in various high throughput screening strategies against recombinant proteins, reconstituted formats, living cells, etc. Of note, we have established a novel transgenic mouse strain that can produce fully human anti-GPCR antibodies, which can greatly facilitate therapeutic/diagnostic antibody discovery.
Creative Biolabs offers all-around phage display library construction and library screening service. Equipped with this world-leading phage display platform, dozens of references can be tracked for whom we have successfully generated good antibodies. Moreover, we have rich experience in conducting versatile biopanning strategies, including in-solution panning, solid-phase panning, cell-based panning, in vivo panning, etc.
Fig 2 Screening technologies for the isolation of anti-GPCR antibodies. (a) Immunization of laboratory animals with various types of GPCR antigens. (b) High-throughput antibody display technologies. (Jo M and Jung ST, 2016)
Creative Biolabs carries multiple well-tailored premade antibody libraries of various formats (scFv/Fab/VHH) to fulfill your needs. These libraries have great capacity and diversity that are able to derive excellent antibody binders with affinity ranging from 10 nM to 10 pM.
Based on antigen-specific B cell sorting technology, this unique Native™ antibody discovery platform aims at developing native monoclonal antibodies with naturally paired heavy chain and light chain. Aided by this technology, we are capable of enriching a large pool of native anti-GPCR IgGs form immunized hosts within a short period of time. Plenty of host species are now available including human, rat, mouse, rabbit, chicken, etc.
Empowered by these approaches, Creative Biolabs is confident in offering the most professional support to our clients regarding anti-GPCR antibody development. In addition, our scientists are also offering comprehensive GPCR immunogen preparation service in diverse formats such as liposomes, nanodiscs, polymers, designed peptide, stable cell lines, etc. With rich experiences for hundreds of successful cases, our skilled technical teams are capable of all kinds of troubleshooting throughout the process. Please feel free to contact us for more information.